This narrative review examined the role of probiotics in patients with sepsis. The authors did not report a specific study size or population because this was a review of existing literature rather than a new trial. The main finding is that clinicians should prioritize source control and antibiotic stewardship when treating sepsis.
The review advises against using live probiotics in high-risk sepsis cases. This caution comes from the need to manage infection carefully in critically ill patients. The authors did not report specific safety data or adverse events from a new study, as this was a summary of prior information.
Readers should understand that this guidance focuses on standard infection management. The primary recommendation is to avoid live probiotics for those at high risk. This approach aligns with current best practices for managing severe infections. The review does not claim to prove new benefits but rather reinforces existing safety priorities.